Exact Sciences Continues to Surprise to the Upside
Exact Sciences (NASDAQ: EXAS) reported second-quarter financial results today that exceeded industry-watchers' forecasts, continuing a string of successes that has frustrated short-sellers and caused shares to more than double in the past year. Can this company continue its winning ways?
Tens of millions of Americans who should get tested for colon cancer simply aren't doing it. Despite the ability of a colonoscopy to catch colon cancer early, and a much-improved rate of survival when colon cancer is identified in its earliest stages, many patients consider colonoscopies to be too invasive, too costly, and too preparation-intensive.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Exact Sciences Aktie
59,16 €
-3,07 %
Die Community bevorzugt Exact Sciences mit mehreren Buy-Einschätzungen und keinen Sell-Einschätzungen.
Ein Kursziel von 76 € für Exact Sciences signalisiert eine potenzielle Steigerung von über 20% gegenüber dem aktuellen Kurs von 59.16 €.
